SEGMENT REPORTING (Tables)

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Schedule of certain information of these segments

	Year ended December 31,
	2012			2011			2010
Revenue
Surgical products	$	59,933		$	59,409		$	59,027
Brachytherapy seed		23,597			24,077			23,752
Intersegment eliminations		(971	)		(756	)		(595	)
	$	82,559		$	82,730		$	82,184
Earnings from operations
Surgical products	$	696		$	607		$	215
Brachytherapy seed		3,122			4,923			3,685
Intersegment eliminations		(51	)		(34	)		(14	)
	$	3,767		$	5,496		$	3,886
Capital expenditures
Surgical products	$	1,357		$	1,780		$	8,316
Brachytherapy seed		565			246			749
	$	1,922		$	2,026		$	9,065
Depreciation and amortization
Surgical products	$	4,917		$	4,536		$	4,686
Brachytherapy seed		2,975			2,689			2,521
	$	7,892		$	7,225		$	7,207

Schedule of supplemental information related to significant assets

	December 31,
	2012			2011
Identifiable assets
Surgical products	$	70,361		$	72,475
Brachytherapy seed		62,474			60,791
Corporate investment in subsidiaries		111,439			111,439
Intersegment eliminations		(138,549	)		(128,887	)
	$	105,725		$	115,818
Intangible assets
Surgical products	$	6,644		$	9,404
Brachytherapy seed		4,376			55
	$	11,020		$	9,459

Schedule of information regarding revenue by geographic regions

	Year ended December 31,
	2012		2011		2010
Product sales
United States	$	69,259	$	70,836	$	71,853
Europe		7,361		7,663		7,544
Other foreign countries		3,388		1,955		1,286
		80,008		80,454		80,683
License and fee income
United States		1,103		953		603
Canada		1,448		1,323		898
		2,551		2,276		1,501
	$	82,559	$	82,730	$	82,184